Skip to main content

Table 4 Effects of clinical variables on the TLR levels in lupus patients (categorical variable)

From: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

 

TLR3

TLR7

TLR8

TLR9

 

Yes

No

Yes

No

Yes

No

Yes

No

 

n

 

n

 

n

 

n

 

n

 

n

 

n

 

n

 

Clinical manifestation

                

   Neuropsychiatric

13

1.3 ± 1.0

33

1.5 ± 1.7

8

3.8 ± 2.8

18

3.9 ± 2.7

13

12 ± 7

33

12 ± 9

13

12 ± 7

33

12 ± 9

   Nephritis

29

1.2 ± 0.7

17

1.8 ± 2.3

17

3.5 ± 2.5

9

4.5 ± 3.0

29

12 ± 9

17

12 ± 9

29

11 ± 8

17

13 ± 9

   Serositis

13

1.3 ± 1.0

33

1.5 ± 1.7

10

3.8 ± 2.3

16

3.9 ± 2.9

13

11 ± 7

33

12 ± 10

13

11 ± 9

33

12 ± 9

   Hematologic

39

1.4 ± 1.6

7

1.4 ± 1.3

22

3.2 ± 2.4

4

5.1 ± 1.7

39

13 ± 9

7

8 ± 4

39

11 ± 8

7

18 ± 10

High-risk HPV infection

11

1.1 ± 0.6

35

1.5 ± 1.7

8

1.9 ± 1.3

18

4.7 ± 2.7 †

11

10 ± 9

35

13 ± 9

11

8 ± 5

35

13 ± 9

Immunosuppressive therapy ever

                

   Prednisolone

                

   Ever

38

1.2 ± 1.0

8

2.4 ± 3.0

22

3.5 ± 2.5

4

5.6 ± 3.0

38

12 ± 8

8

13 ± 10

38

11 ± 9

8

16 ± 9

   Current

36

1.2 ± 0.9

10

2.2 ± 2.7

22

3.8 ± 2.6

4

4.1 ± 3.2

36

12 ± 8

10

12 ± 10

36

12 ± 9

10

11 ± 6

   Hydroxychloroquine

                

   Ever

27

1.1 ± 0.5

19

1.8 ± 2.2

15

2.9 ± 2.4

11

5.2 ± 2.5 †

27

11 ± 7

19

13 ± 11

27

9 ± 7

19

15 ± 10

   Current

16

1.4 ± 1.2

30

1.4 ± 1.7

10

3.6 ± 3.1

16

4.0 ± 2.4

16

13 ± 8

30

11 ± 9

16

12 ± 9

30

12 ± 9

   Azathioprine

                

   Ever

25

1.2 ± 0.6

21

1.7 ± 2.1

16

3.7 ± 2.6

10

4.1 ± 2.8

25

12 ± 9

21

11 ± 8

25

12 ± 10

21

12 ± 7

   Current

8

1.0 ± 0.5

38

1.5 ± 1.6

5

3.4 ± 2.7

21

4.0 ± 2.7

8

9.9 ± 5.6

38

12 ± 9

8

13 ± 12

38

11 ± 8

Cyclophosphamide

(oral or IV)

                

   Ever

6

1.1 ± 0.5

40

1.5 ± 1.6

3

4.2 ± 4.2

23

3.8 ± 2.5

6

7 ± 5

40

13 ± 9

6

8 ± 10

40

12 ± 9

   Current

4

2.1 ± 1.4

42

1.3 ± 1.5

2

N.A.

24

N.A.

4

13 ± 16

42

11 ± 8

4

13 ± 9

42

12 ± 9

   Cyclosporin A

                

   Ever

9

1.5 ± 1.2

37

1.4 ± 1.6

5

4.3 ± 4.2

21

3.8 ± 2.5

9

11 ± 7

37

12 ± 9

9

11 ± 12

37

12 ± 8

   Current

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

   Mycophenolate mofetil

                

   Ever

8

1.3 ± 0.5

38

1.4 ± 1.6

5

2.9 ± 2.8

21

4.1 ± 2.6

8

15 ± 14

38

11 ± 7

8

11 ± 9

38

12 ± 9

   Current

5

1.1 ± 0.5

41

1.5 ± 1.6

3

2.6 ± 3.4

23

4.0 ± 2.6

5

14 ± 10

41

12 ± 8

5

11 ± 9

41

12 ± 9

  1. HPV, human papillomavirus; SLE, systemic lupus erythematosus; TLR, toll-like receptor; † P <0.05
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us